This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Abbott Laboratories (ABT - Free Report) reported second-quarter 2018 adjusted earnings from continuing operations of 73 cents per share, beating the Zacks Consensus Estimate by a couple of cents. The bottom line also improved 17.7% year over year and exceeded the company’s guided range of 70-72 cents. Moreover, reported earnings from continuing operation in the quarter came in at 40 cents per share compared with the year-ago figure of 15 cents.
ABT ALGN ABT GHDX
REUTERS: Abbott Laboratories raised its full-year earnings forecast and topped estimates for quarterly profit on Wednesday, powered by demand for its glucose monitoring device for diabetics and gains from its multibillion dollar acquisitions.
ABT ALR ALR.PRB ABT
REUTERS: Abbott Laboratories raised its full-year earnings forecast and reported a quarterly profit that beat analysts' estimates, powered by higher sales across its businesses.
The market didn’t start Tuesday’s action on the best foot. But, some encouraging words from Federal Reserve Chairman Jerome Powell soothed investors’ worries, pushing stocks collectively back into the black by an average of 0.4%. Overstock.com (NASDAQ:OSTK) led the way with its 10%-plus gain, though beyond, noteworthy pacesetters were few and far between.
ABT OSTK NFLX NYTAB UTX ABT LEG
NORTHVILLE, Mich., July 17, 2018 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader and developer of innovative thermal management technologies, today announced that James Paloyan has joined the Company as Senior Vice President and General Manager of its medical business.
ABT CAH ABT THRM
WALTHAM, Mass., July 16, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Chhaya Shah as Senior Vice President of Technical Operations.
ABT SGYP SGYPW RDUS ABT
The first half of 2018 is already over, so it is time to look back at how our portfolio performed, the purchases we made and to check our income growth.
SOJA LMT GIS XOM O.PRF TWX OPRF CVS ABT NKE HON AAPL ABBV DIS ABT VTR HON SO GILD O MA TWC RB CMI TGT V AFL PEP JNJ CVX DG MSFT SBUX ABBV QCOM
Abbott Laboratories’ (ABT - Free Report) Established Pharmaceuticals Division (EPD) business has been recording operational sales growth in the last few quarters. We expect this strength to further get reflected in second-quarter 2018 results, scheduled for release on Jul 18.
ABT RMD SYK MCK RSMDF RMD ABT
After initially invalidating the rule in March, the Fifth Circuit Court of Appeals officially issued an order vacating the rule on June 21st.
WFCNP MS.PRE WFC.PRL MS.PRF NFLX WFC.PRJ MS.PRG MS.PRA ABT BAC WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN MS WFC.PRY WFC.PRX WFC.PRW WFC.PRV ABT WFC WFC.WS BAC LOGM MS.PRI MS.PRK
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to LSE:ABT / ABBOTT LABORATORIES on message board site Silicon Investor.